Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure
How to buy Amgen stock
Learn how to easily invest in Amgen stock.
Amgen Inc is a drug manufacturers-general business based in the US. Amgen shares (AMGN) are listed on the NASDAQ and all prices are listed in US Dollars. Amgen employs 24,200 staff and has a trailing 12-month revenue of around $26.4 billion.
How to buy shares in Amgen
- Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
- Open your brokerage account. Complete an application with your details.
- Confirm your payment details. Fund your account.
- Research the stock. Find the stock by name or ticker symbol – AMGN – and research it before deciding if it's a good investment for you.
- Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
- Check in on your investment. Optimize your portfolio by tracking your stock.
What's in this guide?
- AMGN shares summary
- Compare share dealing platforms
- Is AMGN stock a buy or sell?
- Stock performance over time
- Is AMGN suitable for ethical investing?
- Are AMGN shares over-valued?
- Amgen's financials
- How volatile are AMGN shares?
- Does Amgen pay a dividend?
- Have AMGN shares ever split?
- Other common questions
Amgen stock price (NASDAQ: AMGN)Use our graph to track the performance of AMGN stocks over time.
Amgen shares at a glance
|Latest market close||$226.97|
|52-week range||$193.88 - $255.99|
|50-day moving average||$244.71|
|200-day moving average||$237.37|
|Wall St. target price||$253.12|
|Dividend yield||$7.4 (3.36%)|
|Earnings per share (TTM)||$11.76|
Buy Amgen shares from these brokeragesCompare special offers, low fees and a wide range of types of investments among top trading platforms.
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
Is it a good time to buy Amgen stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Amgen price performance over time
|1 week (2022-09-16)||-1.80%|
|1 month (2022-08-24)||-7.17%|
|3 months (2022-06-24)||-7.50%|
|6 months (2022-03-24)||-4.18%|
|1 year (2021-09-23)||5.54%|
|2 years (2020-09-24)||-5.56%|
|3 years (2019-09-24)||15.48%|
|5 years (2017-09-22)||22.18%|
Is Amgen stock undervalued or overvalued?
Valuing Amgen stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Amgen's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Amgen's P/E ratio
Amgen's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 20x. In other words, Amgen shares trade at around 20x recent earnings.
That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.
Amgen's PEG ratio
Amgen's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 1.3142. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Amgen's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
Amgen's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $13.2 billion.
The EBITDA is a measure of a Amgen's overall financial performance and is widely used to measure a its profitability.
|Revenue TTM||$26.4 billion|
|Operating margin TTM||37.75%|
|Gross profit TTM||$19.5 billion|
|Return on assets TTM||10.46%|
|Return on equity TTM||123.31%|
|Market capitalisation||$123.4 billion|
TTM: trailing 12 months
Amgen's environmental, social and governance track record
Environmental, social and governance (known as ESG) criteria are a set of three factors used to measure the sustainability and social impact of companies like Amgen.
When it comes to ESG scores, lower is better, and lower scores are generally associated with lower risk for would-be investors.
Amgen's total ESG risk score
Total ESG risk: 20.95
Socially conscious investors use ESG scores to screen how an investment aligns with their worldview, and Amgen's overall score of 20.95 (as at 12/31/2018) is pretty good – landing it in it in the 24th percentile of companies rated in the same sector.
ESG scores are increasingly used to estimate the level of risk a company like Amgen is exposed to within the areas of "environmental" (carbon footprint, resource use etc.), "social" (health and safety, human rights etc.), and "governance" (anti-corruption, tax transparency etc.).
Amgen's environmental score
Environmental score: 1.53/100
Amgen's environmental score of 1.53 puts it squarely in the 3rd percentile of companies rated in the same sector. This could suggest that Amgen is a leader in its sector terms of its environmental impact, and exposed to a lower level of risk.
Amgen's social score
Social score: 15.13/100
Amgen's social score of 15.13 puts it squarely in the 3rd percentile of companies rated in the same sector. This could suggest that Amgen is a leader in its sector when it comes to taking good care of its workforce and the communities it impacts.
Amgen's governance score
Governance score: 5.8/100
Amgen's governance score puts it squarely in the 3rd percentile of companies rated in the same sector. That could suggest that Amgen is a leader in its sector when it comes to responsible management and strategy, and exposed to a lower level of risk.
Amgen's controversy score
Controversy score: 2/5
ESG scores also evaluate any incidences of controversy that a company has been involved in. Amgen scored a 2 out of 5 for controversy – the second-highest score possible, reflecting that Amgen has, for the most part, managed to keep its nose clean.
Environmental, social, and governance (ESG) summary
|Total ESG score||20.95|
|Total ESG percentile||23.7|
|Environmental score percentile||3|
|Social score percentile||3|
|Governance score percentile||3|
|Level of controversy||2|
Amgen share dividends
Dividend payout ratio: 42.28% of net profits
Recently Amgen has paid out, on average, around 42.28% of net profits as dividends. That has enabled analysts to estimate a "forward annual dividend yield" of 3.36% of the current stock value. This means that over a year, based on recent payouts (which are sadly no guarantee of future payouts), Amgen shareholders could enjoy a 3.36% return on their shares, in the form of dividend payments. In Amgen's case, that would currently equate to about $7.4 per share.
While Amgen's payout ratio might seem fairly standard, it's worth remembering that Amgen may be investing much of the rest of its net profits in future growth.
Amgen's most recent dividend payout was on 7 September 2022. The latest dividend was paid out to all shareholders who bought their shares by 16 August 2022 (the "ex-dividend date").
Have Amgen's shares ever split?
Amgen's shares were split on a 2:1 basis on 21 November 1999. So if you had owned 1 share the day before before the split, the next day you'd have owned 2 shares. This wouldn't directly have changed the overall worth of your Amgen shares – just the quantity. However, indirectly, the new 50% lower share price could have impacted the market appetite for Amgen shares which in turn could have impacted Amgen's share price.
Amgen share price volatility
Over the last 12 months, Amgen's shares have ranged in value from as little as $193.8842 up to $255.993. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Amgen's is 0.5637. This would suggest that Amgen's shares are less volatile than average (for this exchange).
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces the chance of infection due a low white blood cell count in patients cancer; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Aranesp to treat a lower-than-normal number of red blood cells and anemia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; and Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization. It also markets Nplate, Vectibix, MVASI, Parsabiv, EPOGEN, KANJINTI, BLINCYTO, Aimovig, EVENITY, AMGEVITATM, Sensipar/Mimpara, NEUPOGEN, IMLYGIC, Corlanor, and AVSOLA. Amgen Inc. serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies.
Amgen in the news
Amgen (NASDAQ:AMGN) shareholders have earned a 7.3% CAGR over the last five years
Amgen (AMGN) Stock Moves -1.43%: What You Should Know
Novartis (NVS) Unit Posts Positive Results on Prolia Biosimilar
Frequently asked questionsWhat percentage of Amgen is owned by insiders or institutions?
Currently 0.216% of Amgen shares are held by insiders and 80.114% by institutions. How many people work for Amgen?
Latest data suggests 24,200 work at Amgen. When does the fiscal year end for Amgen?
Amgen's fiscal year ends in December. Where is Amgen based?
Amgen's address is: One Amgen Center Drive, Thousand Oaks, CA, United States, 91320-1799 What is Amgen's ISIN number?
Amgen's international securities identification number is: US0311621009 What is Amgen's CUSIP number?
Amgen's Committee on Uniform Securities Identification Procedures number is: 031162100
More guides on Finder
What are the FAANG stocks and how do you invest in them?
Looking to invest in tech? Here’s how to buy shares in the major tech companies, known as FAANG stocks.
How to buy soccer stocks
A simple guide to buying stocks in your favorite European soccer team.
How to buy Juventus stock
Steps to owning and managing JUVE, with 24-hour and historical pricing before you buy.
How to buy AS Roma stock
Steps to owning and managing ASR, with 24-hour and historical pricing before you buy.
How to buy Borussia Dortmund stock
Steps to owning and managing BVB, with 24-hour and historical pricing before you buy.
How to buy Lead Real Estate Co. (LRE) stock when it goes public
Everything we know about the Lead Real Estate Co. IPO, plus information on how to buy in.
How to buy Third Harmonic Bio (THRD) stock
Everything we know about the Third Harmonic Bio IPO, plus information on how to buy in.
How to buy LINKBANCORP (LNKB) stock
Everything we know about the LINKBANCORP IPO, plus information on how to buy in.
Here are the stocks that benefit from inflation, as well as industries to keep an eye on to reduce the impacts of inflation on your portfolio.
We’ve rounded up stats on some of the most popular wheat stocks, along with information on how these stocks compare and how to invest.
Ask an Expert